SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gains on plan to invest Rs 100 crore for expansion of its quick-service restaurant business

09 May 2016 Evaluate

Ajanta Pharma is currently trading at Rs. 1546.80, up by 4.65 points or 0.30% from its previous closing of Rs. 1542.15 on the BSE.

The scrip opened at Rs. 1551.00 and has touched a high and low of Rs. 1558.45 and Rs. 1536.20 respectively. So far 6447 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 1103.00 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 1558.45 and Rs. 1460.65 respectively. The current market cap of the company is Rs. 13660.58 crore.

The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 11.67% and 14.55% respectively.

In a bid to expand its quick-service restaurant business Wok Express, Ajanta Pharma will invest over Rs 100 crore. The company is planning to expand its presence in Mumbai and making an entry in four places, including New Delhi and Bengaluru.

So far, the company has invested about Rs 6 crore on setting up and operating its five outlets in Mumbai. Inspired by ‘Wok to Walk’, a restaurant in New York that allows customers to make their own Asian recipes, Wok Express will compete with Chinese restaurants such as Yo! China and other QSR brands.

Ajanta Pharma is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries.

Ajanta Pharma Share Price

3032.20 -48.00 (-1.56%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×